Research-Article

You have full text access to this OnlineOpen article

Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study

  1. Charles H Chesnut III MD1,†,*,
  2. Sharmilla Majumdar2,
  3. David C Newitt2,
  4. Andrew Shields1,
  5. Jan Van Pelt1,
  6. Ellen Laschansky1,
  7. Moise Azria3,
  8. Audrey Kriegman4,
  9. Melvin Olson3,
  10. Erik F Eriksen3,
  11. Linda Mindeholm3

Article first published online: 27 APR 2005

DOI: 10.1359/JBMR.050411

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 20, Issue 9, pages 1548–1561, September 2005

Additional Information

How to Cite

Chesnut, C. H., Majumdar, S., Newitt, D. C., Shields, A., Van Pelt, J., Laschansky, E., Azria, M., Kriegman, A., Olson, M., Eriksen, E. F. and Mindeholm, L. (2005), Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study. J Bone Miner Res, 20: 1548–1561. doi: 10.1359/JBMR.050411

Author Information

  1. 1

    Osteoporosis Research Group, Department of Radiology (UWMC-ORG), University of Washington Medical Center, Seattle, Washington, USA

  2. 2

    Magnetic Resonance Science Center, Department of Radiology, University of California at San Francisco, San Francisco, California, USA

  3. 3

    Novartis Pharmaceuticals, Basle, Switzerland

  4. 4

    Novartis Pharmaceuticals, East Hanover, New Jersey, USA

  1. †

    Dr Chesnut serves as a consultant for Novartis. Drs Olson, Mindeholm, Eriksen, Kriegman, and Azria are employees of and own stock in Novartis. All other authors have no conflict of interest.

*Osteoporosis Research Group University of Washington Medical Center 1107 NE 45th Street, Suite 440 Seattle, WA 98105–4631, USA

  1. †

    Dr Chesnut serves as a consultant for Novartis. Drs Olson, Mindeholm, Eriksen, Kriegman, and Azria are employees of and own stock in Novartis. All other authors have no conflict of interest.

Publication History

  1. Issue published online: 4 DEC 2009
  2. Article first published online: 27 APR 2005
  3. Manuscript Accepted: 21 APR 2005
  4. Manuscript Revised: 20 APR 2005
  5. Manuscript Received: 8 JUN 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (681K)

References

  • 1
    National Institutes of Health (NIH) Consensus Development Panel 2000 Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement. Available online at http://consensus.nih.gov. Accessed 2001.
  • 2
    Chesnut CH, Rosen CJ 2001 Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture (Perspective). J Bone Miner Res 16:2163–2172.
  • 3
    Delmas PD 2000 How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27:1–3.
  • 4
    Riggs BL, Melton LJ 2002 Bone turnover matters: The raloxofene paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11–14.
  • 5
    Chesnut CH, Silverman S, Andriano K, Genant HK, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fracture study. Am J Med 109:267–276.
  • 6
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637–645.
  • 7
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10.
  • 8
    Cummings SR, Karpf DB, Harris SF, Genant HK, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 112:281–289.
  • 9
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610.
  • 10
    Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P 1999 Direct three-dimensional morphometric analysis of human cancellous bone: Microstructural data from spine, femur, iliac crest and calcaneus. J Bone Miner Res 14:1167–1174.
  • 11
    Newitt DC, Majumdar S, Van Rietbergen B, von Ingersleben G, Harris ST, Genant HK, Chesnut C, Garnero P, MacDonald B 2002 In vivo assessment of architecture and micro-finite element analysis derived indices of mechanical properties of trabecular bone in the radius. Osteoporos Int 13:6–17.
  • 12
    Wald LL, Carvajal L, Moyher SE 1995 Phased array detectors and an automated intensity-correction algorithm for high-resolution MR imaging of the human brain. Magn Reson Med 34:433–439.
  • 13
    Newitt D, Majumdar S 2000 A Semi-Automated System for Segmenting, Registering, Thresholding, and Analyzing High Resolution MRI of Trabecular Bone, Proceedings of the 8th Annual Meeting of the ISMRM 2000, Denver, Colorado.
  • 14
    Majumdar S, Genant HK, Grampp S, Newitt DC, Truong VH, Lin JC, Mathur A 1997 Correlation of trabecular bone structure with age, bone mineral density, and osteoporotic status: In vivo studies in the distal radius using high resolution magnetic resonance imaging. J Bone Miner Res 12:111–118.
  • 15
    Majumdar S, Kothari M, Augat P, Newitt DC, Link TM, Lin JC, Lang T, Lu Y, Genant HK 1998 High-resolution magnetic resonance imaging: Three-dimensional trabecular bone architecture and biomechanical properties. Bone 22:445–454.
  • 16
    Hildebrand T, Ruegsegger P 1997 A new method for the model independent assessment of thickness in three-dimensional images. J Microsc 185:245–246.
  • 17
    Newitt D, Van Rietbergen B, Majumdar S 2002 Processing and analysis of in vivo high-resolution MR images of trabecular bone for longitudinal studies: Reproducibility of structural measures and micro-finite element analysis derived mechanical properties. Osteoporos Int 13:278–287.
  • 18
    Eriksen EF 1986 Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379–408.
  • 19
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen E 2003 Recombinant human parathyroid hormone (1-34) (Teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941.
  • 20
    Jiang Y, Zhao J, Genant HK 2002 Macro and micro imaging of bone architecture. In: BilezikianJP, RaiszLG, RodanGA (eds.) Principles of Bone Biology, 2nd ed. Academic Press, San Diego, CA, USA, pp. 1599–1623.
  • 21
    Majumdar S, Link TM, Augat P, Lin JC, Newitt D, Lu Y, Lane NE, Genant HK 1999 Trabecular bone architecture in the distal radius using magnetic resonance imaging in subjects with fractures of the proximal femur. Osteoporos Int 10:231–239.
  • 22
    Vedi S, Compston JE 1996 The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women. Bone 19:535–539.
  • 23
    Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F 1989 A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10:313–320.
  • 24
    Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B 2003 Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423–432.
  • 25
    Masarachia P, Howard T, Santora A, Yates J, Rodan GA, Recker RR, Kimmel DB 2003 Alendronate increases trabecular bone connectivity in elderly osteoporotic women. J Bone Miner Res 18:S2–S372.
  • 26
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates JA, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480.
  • 27
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846–1853.
  • 28
    Melson F, Melson B, Mosekilde L 1978 An evaluation of the quantitative parameters applied in bone histology. Acta Pathol Microbiol Scand 86:63–69.
  • 29
    Ulrich D, Van Rietbergen B, Laib A, Ruegsegger P 1999 The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone 25:55–60.
  • 30
    Beuf O, Newitt DC, Mosekilde L, Majumdar S 2001 Trabecular structure assessment in lumbar vertebrae specimens using quantitative magnetic resonance imaging and relationship to mechanical competence. J Bone Miner Res 16:1511–1519.
  • 31
    Wehrli FW, Gomberg BR, Saha PK, Song HK, Hwang SN, Snyder PJ 2001 Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. J Bone Miner Res 16:1520–1531.
  • 32
    Link TM, Majumdar S, Lin JC, Newitt D, Augat P, Ouyang A, Mathur A, Genant HK 1998 A comparative study of trabecular bone properties in the spine and femur using high resolution MRI and CT. J Bone Miner Res 13:122–132.
  • 33
    Wehrli FW, Popescu AM, Vasilic B, Gomberg BR, Saha PK, Zemel B, Bunker B, Wright AC, Snyder PJ, Peachy H 2003 Longitudinal changes in trabecular bone architecture detected by micro-MRI based virtual bone biopsy. J Bone Miner Res 18:S2–S27.
  • 34
    Parfitt AM 1992 Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13:S41–S47.
  • 35
    Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM 1985 The role of three-dimensional trasbecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594–597.
  • 36
    Ciarelli TE, Fyhrie DP, Schaffler MB, Goldstein SA 2000 Variations in three-dimensional cancellous bone architecture of the proximal femur in female hip fractures and in controls. J Bone Miner Res 15:32–40.
  • 37
    Legrand E, Chappard D, Pascaretti C, Duquenne M, Krebs S, Rohmer V, Basle M-F, Audran M 2000 Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 15:13–19.
  • 38
    Jiang Y, Zhao J, Geusens P, Liao E-Y, Andriaensens P, Gelan J, Azria M, Boonen S, Caulin F, Lynch JA, Ouyang X, Genant HK 2005 Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation. J Bone Miner Res 20:125–130.
  • 39
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevett MC, Bauer DC, Genant GK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541.
  • 40
    Majumdar S, Genant HK, Grampp S, Newett DC, Truong VH, Lin JC, Mathur A 1997 Correlations of trabecular bone structure with age, bone mineral density, and osteoporotic status: In vivo studies in the distal radius using high resolution magnetic resonance imaging. J Bone Miner Res 12:111–118.
  • 41
    Thomsen JS, Ebbeson EN, Mosekilde L 2002 Zone-dependent changes in human vertebral trabecular bone: Clinical implications. Bone 30:664–669.
  • 42
    Pistoia W, Van Rietbergen B, Lochmuller E-M, Lill CA, Eckstein F, Ruegsegger P 2002 Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images. Bone 30:842–846.
  • 43
    Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ 2004 Acute effects of calcitonin nasal spray on serum serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int 75:477–481.
  • 44
    Zikan V, Stepan JJ 2002 Plasma type 1 collagen cross-linked C-telopeptide: A sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 316:63–69.
  • 45
    Overgaard K 1994 Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 55:82–86.
  • 46
    Tanko LB, Bagger YZ, Alexanderson P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C 2004 Safety and efficacy of a novel Eligen technology-based oral formulation of salmon calcitonin in healthy postmenopausal women: Acute and three-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–1538.
  • 47
    Farley JR, Tarbaux NM, Hall SL, Linkhart TA, Baylink DJ 1988 The anti-bone-resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation. Endocrinology 123:159–167.
  • 48
    Furuichi H, Fukuyama R, Izumo N, Fujita T, Kohno T, Nakamuta H, Koida M 2000 Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Biol Pharm Bull 23:946–951.
View Full Article (HTML) Get PDF (681K)